Physician profile
Calin Moucha
NPI 1528142197
$6,316.12
in general payments reported to CMS, 2019-2025
10 companies · $640 in 2025
The $640 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2021: $60.66 · 2022: $320 · 2023: $731 · 2024: $4,286 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,630 · Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,630.00 |
| Food and Beverage | $2,026.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $3,878.33 | 2023-2024 | Velys, Attune |
| Depuy Synthes Sales INC. | $997.80 | 2021-2025 | Attune, Kincise, Velys |
| Innovation Technologies INC | $333.12 | 2023-2024 | Irrisept |
| Davol INC. | $331.44 | 2025 | Arista |
| Smith+Nephew, INC. | $306.19 | 2019-2023 | Real Intelligence |
| Stryker Corporation | $168.47 | 2022-2023 | Mako |
| Medtronic, INC. | $128.88 | 2023 | Cd Horizon Spinal System |
| Vertex Pharmaceuticals Incorporated | $107.25 | 2025 | |
| Zimmer Biomet Holdings, INC. | $43.16 | 2021-2022 | |
| Heron Therapeutics, INC. | $21.48 | 2025 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calin Moucha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.